Quest Diagnostics Incorporated (DGX) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Hold
Based on 34 analysts3.9% Below Target
DGX trades 3.9% below Wall Street's consensus target of $220.57.
Current Price$212.38
Average Target$220.57
Target
Current
Low$210.00
Median$220.00
High$235.00
Analyst Target Range
Forward P/E19.8x
(Fair)
PEG Ratio—
Implied Growth+17.6%
(Moderate)
Analyst Spread11.3%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes DGX achieves its forward estimates and maintains a stable P/E multiple of 19.8x. This scenario reflects the blended consensus of 34 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
DGX Price Target Analysis
Updated July 8, 2026As of July 8, 2026, Quest Diagnostics Incorporated (DGX) has a Wall Street consensus price target of $220.57, based on estimates from 34 covering analysts. With the stock currently trading at $212.38, this represents a potential upside of +3.9%. The company has a market capitalization of $23.51B.
Analyst price targets range from a low of $210.00 to a high of $235.00, representing a 11% spread in expectations. The median target of $220.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 13 analysts rating the stock as a Buy or Strong Buy,18 rating it Hold, and 3 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, DGX trades at a trailing P/E of 24.3x and forward P/E of 19.8x. Analysts expect EPS to grow +17.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $244.54, with bear and bull scenarios of $154.06 and $322.20 respectively. Model confidence stands at 55/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+12.8%
Industry Consensus
Avg Forward P/E
83.8x
(High Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 LHLabcorp Holdings Inc. | $23.4B | $283.86 | $311.33 | +9.7% | Buy | 15.8x | 35 |
 SLNOSoleno Therapeutics, Inc. | $2.8B | $53.01 | $80.00 | +50.9% | Buy | 13.9x | 13 |
 EXASExact Sciences Corporation | $20.0B | $104.91 | $105.00 | +0.1% | Buy | 582.8x | 41 |
 BIOBio-Rad Laboratories, Inc. | $7.9B | $292.50 | $321.67 | +10.0% | Buy | 32.4x | 14 |
 NEOGNeogen Corporation | $2.0B | $9.39 | $11.00 | +17.1% | Hold | 25.4x | 11 |
 QDELQuidelOrtho Corporation | $1.2B | $17.00 | $12.25 | -27.9% | Hold | 9.2x | 15 |
 MYRGMYR Group Inc. | $6.5B | $419.08 | $412.67 | -1.5% | Hold | 36.7x | 21 |
 CERSCerus Corporation | $645M | $3.22 | $4.00 | +24.2% | Buy | — | 10 |
 ABTAbbott Laboratories | $166.9B | $95.84 | $125.62 | +31.1% | Buy | 17.5x | 41 |
 TMOThermo Fisher Scientific Inc. | $192.0B | $516.62 | $592.45 | +14.7% | Buy | 20.8x | 42 |
DGX — Frequently Asked Questions
Quick answers to the most common questions about buying DGX stock.
What is the DGX stock price target for 2026?
The consensus price target for DGX is $220.57, close to the current price of $212.38 (3.9% implied move). Based on 34 analyst estimates, the stock appears fairly valued near current levels.
Is DGX a buy, sell, or hold?
DGX has a consensus rating of "Hold" based on 34 Wall Street analysts. The rating breakdown is mixed, with 18 Hold ratings making up the largest segment. The consensus 12-month price target of $220.57 implies 3.9% upside from current levels.
Is DGX stock overvalued or undervalued?
With a forward P/E of 19.7609x, DGX trades at a relatively low valuation. The consensus target of $220.57 implies 3.9% appreciation, suggesting the market may be pricing in risks.
How high can DGX stock go?
The most bullish Wall Street analyst has a price target of $235 for DGX, while the most conservative target is $210. The consensus of $220.57 represents the median expectation. Our quantitative valuation model projects a bull case target of $322 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover DGX stock?
DGX is heavily covered by Wall Street, with 34 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 13 have Buy ratings, 18 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the DGX stock forecast?
The 12-month DGX stock forecast based on 34 Wall Street analysts shows a consensus price target of $220.57, with estimates ranging from $210 (bear case) to $235 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $245, with bear/bull scenarios of $154/$322.
What is DGX's fair value based on fundamentals?
Our quantitative valuation model calculates DGX's fair value at $245 (base case), with a bear case of $154 and bull case of $322. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 55/100.
What is DGX's forward P/E ratio?
DGX trades at a forward P/E ratio of 19.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 24.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy DGX stock?
DGX appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $220.57 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do DGX price targets vary so much?
DGX analyst price targets range from $210 to $235, a 11% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $220.57 consensus represents the middle ground. Our model's $154-$322 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare